A
NTLA icon

AlphaQuest’s Intellia Therapeutics NTLA Stock Holding History

AlphaQuest’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-27,588
Closed -$248K – 1370
2025
Q4 		$248K Buy
27,588
+11,712
+74% +$161K 0.01% 1339
2025
Q3 		$274K Sell
15,876
-6,339
-29% -$78.1K 0.02% 1220
2025
Q2 		$208K Sell
22,215
-29,619
-57% -$243K 0.02% 1101
2025
Q1 		$369K Buy
51,834
+31,096
+150% +$314K 0.04% 672
2024
Q4 		$242K Buy
20,738
+990
+5% +$15.4K 0.03% 792
2024
Q3 		$406K Buy
19,748
+12,734
+182% +$294K 0.04% 754
2024
Q2 		$157K Sell
7,014
-2,793
-28% -$66.5K 0.02% 824
2024
Q1 		$270K Sell
9,807
-609
-6% -$16.9K 0.05% 555
2023
Q4 		$318K Buy
+10,416
New +$299K 0.07% 495

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return